PMID- 38074659
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231211
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients 
      with transarterial chemoembolization- refractory hepatocellular carcinoma: a 
      two-center retrospective study.
PG  - 1231359
LID - 10.3389/fonc.2023.1231359 [doi]
LID - 1231359
AB  - OBJECT: To investigate the efficacy and safety of tyrosine kinase inhibitors 
      (TKIs: sorafenib and lenvatinib) plus PD-1 inhibitor (camrelizumab) versus TKIs 
      alone in transarterial chemoembolization-refractory (TACE-refractory) 
      hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Data of TACE-refractory 
      HCC patients treated with TACE+TKIs+PD-1 inhibitor (TACE+TKIs+PD-1group) (n=57) 
      or TACE+TKIs (TACE+TKIs group) (n=50) from January 2019 to January 2022 were 
      retrospectively collected and analyzed. The differences in overall survival (OS), 
      progression-free survival (PFS), tumor responses (based on modified Response 
      Evaluation Criteria in Solid Tumors) and adverse events (AEs) were compared 
      between the two groups. Potential factors affecting OS and PFS were evaluated by 
      univariate and multivariate analyses. RESULTS: Compared with the TKIs group, both 
      PFS and OS were prolonged in the TACE+TKIs+PD-1 group (median PFS: 7 months vs. 5 
      months, P=0.007; median OS: 17 months vs. 11 months, P=0.002). In multivariate 
      analysis, tumor size and treatment were independent prognostic factors for PFS 
      and OS. The incidence and severity of AEs related to the treatment between the 
      two groups showed no significant difference. CONCLUSION: The treatment of TACE 
      combined with TKIs plus camrelizumab demonstrated promising efficacy and safety 
      in TACE-refractory HCC.
CI  - Copyright (c) 2023 Gao, Lu and Xiong.
FAU - Gao, Ya
AU  - Gao Y
AD  - Department of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Lu, Haohao
AU  - Lu H
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Xiong, Zhifan
AU  - Xiong Z
AD  - Department of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
LA  - eng
PT  - Journal Article
DEP - 20231122
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10702950
OTO - NOTNLM
OT  - PD-1
OT  - TACE-refractory
OT  - camrelizumab
OT  - hepatocellular carcinoma
OT  - overall survival
OT  - tyrosine kinase inhibitor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/12/11 06:45
MHDA- 2023/12/11 06:46
PMCR- 2023/01/01
CRDT- 2023/12/11 05:46
PHST- 2023/05/30 00:00 [received]
PHST- 2023/11/03 00:00 [accepted]
PHST- 2023/12/11 06:46 [medline]
PHST- 2023/12/11 06:45 [pubmed]
PHST- 2023/12/11 05:46 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1231359 [doi]
PST - epublish
SO  - Front Oncol. 2023 Nov 22;13:1231359. doi: 10.3389/fonc.2023.1231359. eCollection 
      2023.